Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.70 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852228 | 0.89 | HTR2A (0.71) | SIGMAR1DRD2HTR2AHTR2BHTR1A | |
| SCHEMBL7326095 | 0.83 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AALDH1A1HTR2B | |
| SCHEMBL19852369 | 0.78 | SIGMAR1 (0.63) | SIGMAR1DRD2HTR2AALDH1A1HTR2B | |
| SCHEMBL28186295 | 0.75 | SIGMAR1 (0.90) | SIGMAR1DRD2KDM4EALDH1A1HTR2B | |
| SCHEMBL20804357 | 0.75 | SIGMAR1 (0.90) | SIGMAR1DRD2KDM4EALDH1A1HTR2B | |
| SCHEMBL8029650 | 0.75 | SIGMAR1 (0.71) | SIGMAR1DRD2KDM4EALDH1A1HTR2B | |
| SCHEMBL19852136 | 0.75 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR2AHTR1AADRA1D | |
| SCHEMBL667525 | 0.74 | SIGMAR1 (0.63) | SIGMAR1DRD2KDM4EALDH1A1HTR2B | |
| SCHEMBL14076364 | 0.73 | SIGMAR1 (0.79) | SIGMAR1DRD2KDM4EALDH1A1HTR2B | |
| SCHEMBL19852225 | 0.73 | HTR2A (1.00) | SIGMAR1DRD2HTR2AHTR2BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | SIGMAR1 612/4885DRD2 69/4885HTR2A 2/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | SIGMAR1 612/4885DRD2 69/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.